I think the AFR article is ambiguous.
What they are trying to say is that the combined companies will have revenue of $21M & Kaddy did $18M GVM for 1M cases pa.
$18M GVM x 10-15% = $1.8-2.7M revenue. With 21 staff, offices, marketing etc they probably have $3M overheads.
$21M - $1.8-2.7M = $18.3-$19.2M DW8/Partons / 4 = $4.575M - $4.8M Q1 FY2022.
Forecast revenue was 3 x $0.5M DW8 + 2 x $1.25M Partons = $4M so they will be over by about 15-20%.
Dilution from the acquisition is about 21%. Would have been better to wait 6 months, raise at 20c & have about 6% dilution.
It looks like we are getting 10% revenue increase for 21% dilution. However, there is potential for logistics to deliver a portion of the 1M cases pa for Kaddy currently delivered by others. Every 10% equates to 100k cases x $20 = $2M revenue.
The big picture is to do $1B GVM & 9.5M cases pa which equates to 5% market share in Australia.
$1B GVM x 12% fees = $120M pa all gross profit
9.5M cases x $20 = $190M pa x 20% gross profit = $38M gross profit should cover all overheads
5% Australian market share = $310M pa revenue & $158M GP
Allowing for $38M overheads results in $120M EBITDA x 30 = $3.6B MC or about $1.44 SP.
EDV has $12.39B MC / $652M EBITDA = x19 but is a more mature business. $12.93B / $445M NPAT = PE 29.
- Forums
- ASX - By Stock
- Ann: Trading Halt
I think the AFR article is ambiguous.What they are trying to say...
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KDY (ASX) to my watchlist
|
|||||
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.834M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
KDY (ASX) Chart |
Day chart unavailable